无限制治疗方案下磁共振-高强度聚焦超声(MR-HIFU)治疗有症状子宫肌瘤的系统评价与Meta分析
该系统评价与Meta分析检索截至2018年6月22日的多个数据库,纳入18篇文献共1323例接受MR-HIFU治疗的有症状子宫肌瘤患者,排除使用限制性方案或非完全消融目标的研究。结果显示治疗后平均无灌注体积百分比为68.1%,12个月症状平均减轻59.9%、肌瘤缩小37.7%,不良事件发生率8.7%,随访3–33.6个月再干预率为0–21%,生殖结局与成本无法分析。作者认为以完全消融为目标的治疗指南可提高MR-HIFU疗效,但需对照试验明确其在子宫肌瘤管理中的作用。
要点
- 治疗后即刻平均无灌注体积百分比为68.1%,使用肠道干扰缓解策略可能提高该百分比。
- 12个月时症状平均减轻59.9%,肌瘤平均缩小37.7%。
- 不良事件发生率为8.7%,不同HIFU系统间存在差异。
核心结论
- 以完全消融为目标的治疗指南可提高MR-HIFU治疗有症状子宫肌瘤的疗效。
- 作者认为需对照试验明确MR-HIFU在子宫肌瘤管理中的作用。
研究设计与样本
- 系统评价与Meta分析,检索美国国家指南交换中心、Cochrane图书馆、TRIP、MEDLINE、EMBASE及WHO国际临床试验注册平台,检索时间自建库至2018年6月22日。
- 纳入标准为MR-HIFU治疗子宫肌瘤且临床随访至少3个月的研究,排除超声引导HIFU设备治疗或方案不以完全消融为目标的研究。
- 共纳入18篇文章、1323例接受治疗的患者,除一项交叉试验外均为病例系列,证据质量总体为差至中等。
- 采用DerSimonian-Laird随机效应模型进行Meta分析。
关键影像表现/征象
- 治疗后即刻平均无灌注体积百分比(NPV%)为68.1%。
- 使用肠道干扰缓解策略可能提高NPV%。
- 12个月时症状平均减轻59.9%,肌瘤平均缩小37.7%。
诊断标准与关键数值
- 主要结局为肌瘤相关症状改善;技术结局包括筛选与治疗失败、治疗时间、肠道干扰缓解策略的应用及无灌注体积百分比。
- 不良事件发生率为8.7%,分层分析显示不同HIFU系统间存在差异。
- 随访3–33.6个月期间再干预百分比范围为0–21%,随访时间越长再干预风险越高。
临床应用与阅片要点
- 以完全消融为目标的治疗方案与MR-HIFU疗效提高相关。
- 使用肠道干扰缓解策略可能提高无灌注体积百分比。
局限性
- 除一项交叉试验外所有纳入研究均为病例系列。
- 证据质量总体为差至中等。
- 生殖结局与成本无法分析。
- 作者认为需对照试验明确MR-HIFU在子宫肌瘤管理中的作用。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
PURPOSE: Reevaluation of the effectiveness of Magnetic Resonance-High Intensity Focused Ultrasound (MR-HIFU) therapy for uterine fibroids by excluding studies with restrictive treatment protocols that are no longer used.
METHODS: The National Guideline Clearinghouse, Cochrane Library, TRIP, MEDLINE, EMBASE and WHO International Clinical Trials Registry Platform (ICTRP) databases were searched from inception until the 22nd of June 2018. Keywords included "MR-HIFU", "MRgFUS", and "Leiomyoma". Only studies about MR-HIFU treatment of uterine fibroids with at least three months of clinical follow-up were evaluated for inclusion. Treatments with ultrasound-guided HIFU devices or protocols not aiming for complete ablation were eliminated. The primary outcome was the improvement in fibroid-related symptoms. Technical outcomes included screening and treatment failures, treatment time, application of bowel-interference mitigation strategies and the Non-Perfused Volume (NPV) percentage. Other secondary outcomes were the quality of life, fibroid shrinkage, safety, re-interventions, reproductive outcomes, and costs. Meta-analysis was performed using a random-effects model (DerSimonian and Laird).
RESULTS: A total of 18 articles (1323 treated patients) met the inclusion criteria. All selected studies were case series except for one cross-over trial. Overall, the quality of the evidence was poor to moderate. The mean NPV% directly post-treatment was 68.1%. The use of bowel-interference mitigation strategies may lead to increased NPV%. The mean symptom reduction at 12-months was 59.9% and fibroid shrinkage was 37.7%. The number of adverse events was low (8.7%), stratification showed a difference between HIFU systems. The re-intervention percentage at 3-33.6 months follow-up ranged from 0 to 21%. Longer follow-up was associated with a higher risk at re-interventions. Reproductive outcomes and costs couldn't be analyzed.
CONCLUSIONS: Treatment guidelines aiming for complete ablation enhanced the effectiveness of MR-HIFU therapy. However, controlled trials should define the role of MR-HIFU in the management of uterine fibroids.
引用
- Verpalen IM, Anneveldt KJ, Nijholt IM, et al. Magnetic resonance-high intensity focused ultrasound (MR-HIFU) therapy of symptomatic uterine fibroids with unrestrictive treatment protocols: A systematic review and meta-analysis. Eur J Radiol. 2019. PMID: 31634683. doi:10.1016/j.ejrad.2019.108700
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。